While we speak of the recrudescence of new cases of patients reached by the Covid-19, many of them will not realize that they have had the disease. In fact, the study of the university hospital of Karolinska in Stockholm shows that many people infected by the Covid-19 under mild or asymptomatic, have developed an immunity mediated by “T cells” (a type of leukocytes that play a big role in the secondary immune response).
However, these “T cells” have also been found in subjects who have never been in contact with the SARS-CoV-2. The reason, still unknown, could be the result of infection by a coronavirus common (HCoV).
There are seven coronavirus identified. Four of them are widespread in the world, the Alphacoronavirus (229E and NL63) and Betacoronavirus (OC43 and HKU1). They were discovered several years ago, the first in the mid-1960s. The other three are identified from the beginning of the new millennium : SARS-1, MERS, SARS-CoV-2.
A lot of research have focused on the relationship between the T cells and the coronavirus. Some researchers and companies talk about the development of a future vaccine on which there is a lot of speculation, uncertainty medical and polarization of the spirits.
To this day, the vaccines in the course of their research, are not intended as an approach that is specific, personalized and individualized, focusing on a general approach.
The Italian researcher Andrea Savarino, one of the first to study the effects of chloroquine and its derivatives on the SARS virus 1 in 2003, has enrolled for the Covid-19:
His team, from the Istituto Superiore di Sanità Andrea Savarino studied this subject for a time and the progress of their work is such that a patent has been filed.
The optimal approach would thus be an immunization custom against parts of the virus essential to its replication, in order not to disperse the immune response. One of these parts of the virus is the surface glycoprotein Spike on which occur the effects of the drug chloroquine, and derivatives such as hydroxychloroquine.
This drug is able to inhibit the replication of some coronaviruses, at least in vitro. Its action is manifested by the‘inhibition of the attack of a sugar (sialic acid) on the receptor ACE2, the virus continues to enter the cells. A component of their vaccine focuses on the portion of the glycoprotein Spike, which recognizes the sialic acid on the surface of cells to attack”.
It is necessary to better understand the meaning of this concept of’immunization vaccine “tailor-made”, adapted to the different immune responses of individuals :
In fact, decades of research in the study of HIV, were able to establish with relative certainty that all responses mediated by the “cell killer” CD8 + t cells do not lead a defence against the virus. Many can even be counter-productive, because they direct the immune response towards portions changing of the virus, which escape the answer itself. Studies carried out on macaques and humans have shown that the immunity is only effective when it is directed at certain parts of the virus that are not mutable, because they are fundamental to viral replication.
Asked about the timetable for getting to test safety and tolerance in humans, Andrea Savarino, replies :
Peter D’angelo is an author and director of documentaries for television (Rai) and a journalist. He has carried out several investigations for Il Fatto Quotidiano, Corriere della sera, La Repubblica, Panorama, Il Tempo, L’espresso and Il Venerdì.
He has signed a number of investigations for Il Fatto Quotidiano, Corriere della sera, La Repubblica, Panorama, Il Tempo, L’espresso and Il Venerdì. In addition, he has collaborated on several television programs : Report (investigations in prime time), Presadiretta, Le Iene, Petrolio, Mi mandda Raitre and Agorà.
Author(s): Peter D’angelo for FranceSoir